vs
Side-by-side financial comparison of Citius Pharmaceuticals, Inc. (CTXR) and Li Bang International Corp Inc. (LBGJ). Click either name above to swap in a different company.
Li Bang International Corp Inc. is the larger business by last-quarter revenue ($4.7M vs $3.9M, roughly 1.2× Citius Pharmaceuticals, Inc.). Li Bang International Corp Inc. runs the higher net margin — -23.9% vs -238.2%, a 214.3% gap on every dollar of revenue.
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing innovative prescription therapies addressing unmet medical needs across critical care, oncology, anti-infective treatment, and supportive care segments, primarily serving the U.S. healthcare market.
Li & Fung Limited is a Hong Kong–based supply chain management company. Established in 1906, the company became publicly traded in 1973 and has since played a significant role in manufacturing apparel, toys, and various consumer goods for major North American and European retailers. Significant growth occurred after its public listing, reaching a peak market capitalization in 2011, but the rise of platforms like Alibaba and Amazon, which directly connect manufacturers with consumers, created ...
CTXR vs LBGJ — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2024
| Metric | | |
|---|---|---|
| Revenue | $3.9M | $4.7M |
| Net Profit | $-9.4M | $-1.1M |
| Gross Margin | 80.0% | 17.8% |
| Operating Margin | -228.7% | -25.1% |
| Net Margin | -238.2% | -23.9% |
| Revenue YoY | — | — |
| Net Profit YoY | 8.6% | — |
| EPS (diluted) | $-0.38 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.7M | — |
| Total DebtLower is stronger | — | $10.2M |
| Stockholders' EquityBook value | $80.0M | $7.8M |
| Total Assets | $140.4M | $28.8M |
| Debt / EquityLower = less leverage | — | 1.31× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.7M | — | ||
| Q4 24 | — | — |
| Q4 25 | — | — | ||
| Q4 24 | — | $10.2M |
| Q4 25 | $80.0M | — | ||
| Q4 24 | — | $7.8M |
| Q4 25 | $140.4M | — | ||
| Q4 24 | — | $28.8M |
| Q4 25 | — | — | ||
| Q4 24 | — | 1.31× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-13.0M | $258.4K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-13.0M | — | ||
| Q4 24 | — | $258.4K |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
